Screen Shot 2021-01-12 at 7.57.32 PM.png
Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference
January 19, 2021 11:30 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Screen Shot 2021-01-12 at 7.57.32 PM.png
Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
January 13, 2021 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft
December 01, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it...
FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer
November 10, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...
FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
October 27, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that...
FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals’ Lead Compound CPI-613®️ (devimistat) for Patients With Pancreatic Cancer in Japan
October 20, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics announced today its...
Digital Reasoning Offers Oncology Programs Leading AI Solution at Cost Now When Health Systems and Their Cancer Patients Need Help the Most
September 17, 2020 08:00 ET | Digital Reasoning Systems, Inc.
NASHVILLE, Tenn., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Digital Reasoning, the global leader in artificial intelligence solutions that understand human communications and behaviors, announced today...
FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®️ (devimistat) for Patients with Metastatic Pancreatic Cancer
August 06, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...
Rafafel_Pharma_PHP_Graphic_Updated_V3
Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
July 21, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
Cranbury, NJ, July 21, 2020 (GLOBE NEWSWIRE) -- Rafafel_Pharma_PHP_Graphic_Updated_V3 Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer...
Digital Reasoning’s AI Helps Healthcare Providers Avoid Post-COVID Wave of Preventable Cancer Deaths
May 01, 2020 08:15 ET | Digital Reasoning Systems, Inc.
NASHVILLE, Tenn., May 01, 2020 (GLOBE NEWSWIRE) -- Governments, healthcare providers, and others are taking extraordinary measures worldwide to contain and treat COVID-19. However, as an unintended...